Scribe Therapeutics
SCTXScribe Therapeutics is a clinical-stage biotechnology company developing in vivo CRISPR-based genetic medicines for prevalent cardiovascular and metabolic diseases.
Scribe Therapeutics has filed an S-1 registration statement with the SEC and is not yet trading. Financial statements will appear here once it begins reporting as a public company.
S-1 Filings
Registration statements filed with the SEC ahead of the planned listing
Competitors
By market cap
By revenue growth
Profile
Scribe Therapeutics is a clinical-stage biotechnology company developing in vivo CRISPR-based genetic medicines for prevalent cardiovascular and metabolic diseases. The company utilizes a proprietary "CRISPR by Design" engineering approach to create highly specific, durable, and scalable therapies that aim to shift the treatment paradigm from chronic symptom management to population-level disease prevention.
Scribe differentiates itself through its proprietary CasX-based enzyme foundation, which offers a smaller size and higher specificity than traditional Cas9 systems, enabling more efficient delivery and a cleaner safety profile.
Questions, answered.
- Who are Scribe Therapeutics's competitors?
- Scribe Therapeutics's key competitors include Editas Medicine, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does Scribe Therapeutics partner with?
- Scribe Therapeutics's notable partners include Sanofi, Eli Lilly and Company, Prevail Therapeutics, Inc., and others.
- Where is Scribe Therapeutics headquartered?
- Scribe Therapeutics is headquartered in United States of America.